1. Home
  2. WKEY vs RLYB Comparison

WKEY vs RLYB Comparison

Compare WKEY & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WISeKey International Holding Ltd

WKEY

WISeKey International Holding Ltd

HOLD

Current Price

$6.87

Market Cap

94.1M

Sector

Technology

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$15.73

Market Cap

92.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WKEY
RLYB
Founded
1999
2018
Country
Switzerland
United States
Employees
202
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.1M
92.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WKEY
RLYB
Price
$6.87
$15.73
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$10.50
N/A
AVG Volume (30 Days)
83.4K
39.3K
Earning Date
01-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
$31.22
N/A
Revenue Next Year
$91.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$4.75
$0.39
52 Week High
$19.80
$17.57

Technical Indicators

Market Signals
Indicator
WKEY
RLYB
Relative Strength Index (RSI) 42.66 55.98
Support Level $6.43 $15.59
Resistance Level $6.94 $16.50
Average True Range (ATR) 0.43 0.37
MACD -0.02 -0.13
Stochastic Oscillator 21.74 18.68

Price Performance

Historical Comparison
WKEY
RLYB

About WKEY WISeKey International Holding Ltd

WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: